Lupus community panel proposals for optimising clinical trials: 2018.

about

Systemic lupus erythematosus-associated diffuse alveolar hemorrhage: A case report and review of the literature

P2860

Q58390460-2715FAA3-1299-43BD-8146-17542BF12B4D

P2860

Lupus community panel proposals for optimising clinical trials: 2018.

Item

http://www.wikidata.org/entity/Q52320880

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Lupus community panel proposals for optimising clinical trials: 2018.

@en

Lupus community panel proposals for optimising clinical trials: 2018.

@nl

type

Item

label

Lupus community panel proposals for optimising clinical trials: 2018.

@en

Lupus community panel proposals for optimising clinical trials: 2018.

@nl

prefLabel

Lupus community panel proposals for optimising clinical trials: 2018.

@en

Lupus community panel proposals for optimising clinical trials: 2018.

@nl

P1476

Lupus community panel proposals for optimising clinical trials: 2018.

@en

P2093

Anca Askenase

http://www.w3.org/2001/XMLSchema#string

Ben Chong

http://www.w3.org/2001/XMLSchema#string

Brad Rovin

http://www.w3.org/2001/XMLSchema#string

Cynthia Aranow

http://www.w3.org/2001/XMLSchema#string

Eliza Chakravarty

http://www.w3.org/2001/XMLSchema#string

Ellen Ginzler

http://www.w3.org/2001/XMLSchema#string

Joan T Merrill

http://www.w3.org/2001/XMLSchema#string

Joseph Merola

http://www.w3.org/2001/XMLSchema#string

Karen Costenbader

http://www.w3.org/2001/XMLSchema#string

Ken Kalunian

http://www.w3.org/2001/XMLSchema#string

P2860

Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden

Adaptive Designs for Clinical Trials

A highlight from the LUPUS 2014 meeting: eight great ideas

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

Genetics of systemic lupus erythematosus: immune responses and end organ resistance to damage.

Patient-reported outcomes in lupus clinical trials with biologics.

P304

e000258

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/LUPUS-2018-000258

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ian Bruce

Amit Saxena

P577

2018-03-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29657738

http://www.w3.org/2001/XMLSchema#string

P932

5894527

http://www.w3.org/2001/XMLSchema#string

Lupus community panel proposals for optimising clinical trials: 2018.

about

P2860

P2860

Lupus community panel proposals for optimising clinical trials: 2018.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932